entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AccountingPoliciesAreUnchangedFromPreviousPeriod,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AmortisationOfIntangibleAssets,AuditorsReportOnFinancialStatements,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,DateOfApprovalOfAnnualReport,DateOfFoundationOfReportingEntity,DateOfGeneralMeeting,DescriptionOfDevelopmentInActivitiesAndFinancialAffairs,DescriptionOfExpectedDevelopment,DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies,DescriptionOfKnowledgeResources,DescriptionOfMethodsOfAmortisationOfNoncurrentAssets,DescriptionOfMethodsOfForeignCurrencies,DescriptionOfMethodsOfImpairmentLossesAndDepreciation,DescriptionOfMethodsOfLeases,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfProduction,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIncomeStatementItems,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax,DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview,DescriptionOfPrimaryActivitiesOfEntity,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DescriptionOfSpecificRisksInAdditionToCommonlyOccurringHazardsInIndustry,DisclosureOfAccountingPolicies,DisclosureOfContingentLiabilities,DisclosureOfContributedCapital,DisclosureOfDepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss,DisclosureOfEmployeeBenefitsExpense,DisclosureOfIntangibleAssets,DisclosureOfOtherFinanceExpenses,DisclosureOfOtherFinanceIncome,DisclosureOfOtherOperatingExpenses,DisclosureOfOtherPayables,DisclosureOfOwnership,DisclosureOfPropertyPlantAndEquipment,DisclosureOfProvisions,DisclosureOfRevenue,DisclosureOfTaxExpenseOnOrdinaryActivities,Equity,ExplanationOfNotDisclosingCashFlowsStatements,FaxNumberOfReportingEntity,HomepageOfReportingEntity,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IdentificationOfAuditedFinancialStatements,IncreaseDecreaseOfIntangibleAssetsThroughTransfers,IndependentAuditorsReportsAudit,InformationOnAuditorsFees,InformationOnCalculationOfKeyFiguresAndFinancialRatios,InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes,InformationOnSegments,InformationOnTypeOfSubmittedReport,ManagementsStatementAboutManagementsReview,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfAuditFirm,NameOfReportingEntity,NameOfSubmittingEnterprise,OpinionOnAuditedFinancialStatements,PlaceOfSignatureOfStatement,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,StatementByExecutiveAndSupervisoryBoards,StatementOfAuditorsResponsibilityForAuditAndAuditPerformed,StatementOfChangesInEquity,StatementOfCorporateSocialResponsibility,StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements,StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements,TelephoneNumberOfReportingEntity,TitleOfMemberOfSupervisoryBoard,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,AdjustmentsForCurrentTaxOfPriorPeriod,AdjustmentsForDeferredTax,AdministrativeExpenses,AuditorsFees,AverageNumberOfEmployees,CostOfProduction,EmployeeBenefitsExpense,ExtraordinaryDividendPaid,FeesForAuditorsPerformingStatutoryAudit,GrossResult,InterestExpenseAssignedToGroupEnterprises,InterestIncomeFromGroupEnterprises,OtherFinanceExpenses,OtherFinanceIncome,OtherInterestExpenses,OtherInterestIncome,OtherOperatingExpenses,PostemploymentBenefitExpense,ProfitLoss,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,Revenue,SocialSecurityContributions,TaxExpenseOnOrdinaryActivities,WagesAndSalaries,AcquiredIntangibleAssets,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,FixturesFittingsToolsAndEquipment,IntangibleAssets,LandAndBuildings,LeaseholdImprovements,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,NoncurrentAssets,OtherShorttermPayables,OtherShorttermReceivables,PropertyPlantAndEquipment,PropertyPlantAndEquipmentInProgress,Provisions,ProvisionsForDeferredTax,RetainedEarnings,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTradePayables,AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment,PropertyPlantAndEquipmentGross,AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets,IntangibleAssetsGross,AdditionsToPropertyPlantAndEquipment,DepreciationOfPropertyPlantAndEquipment,DisposalsOfPropertyPlantAndEquipment,EquityRatio,GrossMargin,IncreaseDecreaseOfPropertyPlantAndEquipmentThroughTransfers,InvestmentInPropertyPlantAndEquipment,OperatingMargin,ResultsFromNetFinancials,ReturnOnCapitalEmployed,ReturnOnEquity,ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment,DescriptionOfAuditor,NameAndSurnameOfAuditor,NameAndSurnameOfMemberOfSupervisoryBoard
26060702,2013-01-01,2013-01-01,ctx24,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",390000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-01-01,ctx26,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3512011000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-01-01,ctx28,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3512401000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,ctx17,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,-2291000.0,28322000.0,77574000.0,1092000.0,483.0,840078000.0,415820000.0,-143000000.0,1092000.0,214052000.0,401000.0,89000.0,10363000.0,3474000.0,9962000.0,3385000.0,872000.0,26701000.0,102686000.0,128717000.0,135606000.0,1054130000.0,4703000.0,26031000.0,384416000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,ctx19,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,143000000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,ctx21,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,-40314000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-01-01,2013-12-31,ctx30,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,-143000000.0,,,,,,,,,,,102686000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,ctx22,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3472087000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,6485000.0,3784036000.0,71795000.0,390000.0,314038000.0,1280608000.0,6485000.0,1964135000.0,4724000.0,3784036000.0,247784000.0,3469998000.0,123447000.0,2385000.0,3463513000.0,214046000.0,64165000.0,64165000.0,3471697000.0,247784000.0,17090000.0,242243000.0,239858000.0,107247000.0,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,ctx32,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",390000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2013-12-31,2013-12-31,ctx34,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3471697000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx23,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",390000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx25,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3471697000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx27,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3472087000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,609270000.0,4072782000.0,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx35,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16354000.0,22839000.0,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx38,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,346943000.0,2311076000.0,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx39,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1350000.0,6074000.0,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx40,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,260977000.0,1541586000.0,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-01-01,ctx41,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,214046000.0,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx1,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,-2159000.0,43684000.0,95794000.0,1035000.0,552.0,897164000.0,475122000.0,,1035000.0,256586000.0,0.0,1000.0,1162000.0,23664000.0,1162000.0,23663000.0,515000.0,32531000.0,141254000.0,182779000.0,160277000.0,1153750000.0,5487000.0,41525000.0,437104000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,417653000.0,189759000.0,-13692000.0,0.889,0.222,-8407000.0,417653000.0,0.139,22502000.0,0.041,0.04,-904000.0,,,
26060702,2014-01-01,2014-12-31,ctx10,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,209.0,,,,,,,,,,,,,,35956000.0,,38719000.0,365467000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.951,0.253,,70124000.0,0.106,12381000.0,0.01,0.01,,,,
26060702,2014-01-01,2014-12-31,ctx16,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,state authorised public accountant,Rikke Lund-KÃ¼hl,
26060702,2014-01-01,2014-12-31,ctx18,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx2,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inga Birgitte Thygesen
26060702,2014-01-01,2014-12-31,ctx20,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,141254000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx29,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,141254000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx3,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Orkney Stober
26060702,2014-01-01,2014-12-31,ctx36,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx4,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Marianne Leth
26060702,2014-01-01,2014-12-31,ctx42,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,89134000.0,0.0,,,32934000.0,,,,,,0.0,,,
26060702,2014-01-01,2014-12-31,ctx43,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2368000.0,0.0,,,3432000.0,,,,,,0.0,,,
26060702,2014-01-01,2014-12-31,ctx44,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,98257000.0,-13692000.0,,,205967000.0,,,,,,-904000.0,,,
26060702,2014-01-01,2014-12-31,ctx45,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,417653000.0,,0.0,,,-250740000.0,,,,,,0.0,,,
26060702,2014-01-01,2014-12-31,ctx5,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-01-01,2014-12-31,ctx6,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,state authorised public accountant,Torben Jensen,
26060702,2014-01-01,2014-12-31,ctx7,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,483.0,,,,,,,,,,,,,,102686000.0,,135606000.0,1054130000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.918,0.203,,165635000.0,0.129,-6889000.0,0.036,0.029,,,,
26060702,2014-01-01,2014-12-31,ctx8,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,375.0,,,,,,,,,,,,,,49803000.0,,65857000.0,660824000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.933,0.221,,193567000.0,0.1,620000.0,0.018,0.014,,,,
26060702,2014-01-01,2014-12-31,ctx9,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,200.0,,,,,,,,,,,,,,41103000.0,,45576000.0,377812000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.965,0.224,,144528000.0,0.121,6226000.0,0.012,0.012,,,,
26060702,2014-12-31,2014-12-31,ctx11,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3613341000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,12200000.0,4066769000.0,215918000.0,390000.0,384358000.0,1375531000.0,12200000.0,1907933000.0,5788000.0,4066769000.0,345579000.0,3682411000.0,113020000.0,25223000.0,3670211000.0,380959000.0,107849000.0,107849000.0,3612951000.0,345579000.0,21133000.0,168440000.0,143217000.0,211426000.0,798125000.0,4468336000.0,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx12,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3472087000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,3784036000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx13,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3512401000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,3763370000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx14,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3462587000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,3586870000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx15,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3606484000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,3791171000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx31,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",390000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx33,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",3612951000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx37,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12200000.0,,,,,,,,,,,,,,,,,,,,19046000.0,31246000.0,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx46,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1907933000.0,,,,,,,,,,436077000.0,2344010000.0,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx47,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5788000.0,,,,,,,,,,3718000.0,9506000.0,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx48,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1375531000.0,,,,,,,,,,358330000.0,1733861000.0,,,,,,,,,,,,,,,,,
26060702,2014-12-31,2014-12-31,ctx49,,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzLzA1LzI3Lzk0LzFiLzI2NzItNDZhMC1hYTgzLWExZTI3YjNkN2YwOA.pdf,http://regnskaber.virk.dk/20706062/ZG9rdW1lbnRsYWdlcjovLzAzL2E5LzgwL2U4LzE4LzNjMWEtNDZkYS1hYzM0LWJmNDc4Y2E0OWY5Zg.xml,true,Hellerup,2900.0,44.0,Strandvejen,HillerÃ¸d,3400.0,"1,",Biogen AllÃ©,5000 Odense C,Englandsgade 25,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">To the shareholders of Biogen (Denmark) Manufacturing ApS</td></tr></table>",2692000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Report on financial statements</td></tr></table>","Regnskabsklasse C, stor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The annual report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>",2015-05-13,2001-06-01,2015-05-13,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial review</td></tr><tr><td /><td /><td>The Companyâs income statement for the year ended 31 December 2014 shows a net profit of DKK 141,254 thousand and the balance sheet at 31 December 2014 shows equity of DKK 3,613,341 thousand.</td></tr><tr><td /><td /><td>In June 2013 the pharmaceutical production received licensure from the authorities to be able to do commercial production. During 2013 and 2014 the pharmaceutical production has increased significantly.  The labelling and packaging and quality control activities continued to expand in 2014.</td></tr><tr><td /><td /><td>During 2014, the Company employed an average of 552 full&#x1E;time employees, compared to an average of 483 full&#x1E;time employees in 2013.</td></tr><tr><td /><td /><td>The current yearâs revenue, DKK 1,153 million, primarily derives from contract manufacturing fees related to bulk production and labeling and packaging of biological products, as well as related quality control activities.</td></tr><tr><td /><td /><td>The net profit for the year is consistent with the expectations expressed at the beginning of the year. The increase in profit is primarily resulted from the increase in revenue, noted above.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Outlook</td></tr><tr><td /><td /><td>It is expected that the activities in the labelling &amp; packaging and associated quality functions will continue at approximately the same level, subject to demand&#x1E;based fluctuations inherent in the pharmaceutical industry.</td></tr><tr><td /><td /><td>The pharmaceutical production is expected to increase in 2015 since increased production facilities are expected to be in service late 2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Recognition and measurement in general</td></tr><tr><td /><td /><td>The annual report has been prepared under the historical cost method.  Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.  Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.  Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.  Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Knowledge resources</td></tr><tr><td /><td /><td>The Company is operating in the area of biotechnological products with a high degree of specialised knowledge.</td></tr><tr><td /><td /><td>Production and infrastructure are subject to the health authoritiesâ strict product requirements relating to drugs for patient treatment purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Impairment of fixed assets</td></tr><tr><td /><td /><td>Every year, intangible assets and property, plant and equipment are reviewed for impairment.  Where there is indication of impairment, an impairment test is made for each individual asset or group of assets, respectively, generating independent cash flows. The assets are written down to the higher of the value in use and the net selling price of the asset or group of assets (recoverable amount) if it is lower than the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Currency translation</td></tr><tr><td /><td /><td>Transactions denominated in foreign currencies are translated into Danish kroner at the exchange rate at the date of the transaction.</td></tr><tr><td /><td /><td>Receivables, payables and other monetary items denominated in foreign currencies are translated into Danish kroner at the exchange rate at the balance sheet date. Realised and unrealised exchange gains and losses are recognised in the income statement as financial income/expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td /><td /><td>The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.</td></tr><tr><td /><td /><td>Intangible assets are amortised on a straight&#x1E;line basis over the expected useful life of each individual asset.</td></tr><tr><td /><td /><td>The estimated useful lives for intangible assets are as follows</td></tr><tr><td /><td /><td>Property, plant and equipment are depreciated on a straight&#x1E;line basis over the expected useful life of each individual asset. The depreciation basis is the cost plus revaluations.</td></tr><tr><td /><td /><td>The expected useful lives of the assets are as follows</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Leases</td></tr><tr><td /><td /><td>Leases concerning fixed assets which qualify for recognition as assets held under finance leases and where the entity bears all significant risks and enjoys all significant benefits associated with the title to such assets are treated according to the same accounting policies as are other fixed assets.</td></tr><tr><td /><td /><td>On initial recognition, the cost of assets held under finance leases is measured at the lower of the fair value and the net present value of the lease payments, made up based on the interest rate implicit in the lease or, alternatively, the entity's borrowing rate.</td></tr><tr><td /><td /><td>Commitments under finance leases are recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement.</td></tr><tr><td /><td /><td>Leases in respect of which the entity does not bear all significant risks and enjoy all significant benefits associated with the title to the assets are considered operating leases. Payments under operating leases are recognised in the income statement over the term of the lease.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Administrative expenses</td></tr><tr><td /><td /><td>Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Balance sheet</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Cash and cash equivalents</td></tr><tr><td /><td /><td>Cash comprises cash balances and bank balances.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Production costs</td></tr><tr><td /><td /><td>Production costs comprise expenses incurred to pack and label the products. Production costs include materials, direct wages and production overheads such as maintenance costs, amortisation, depreciation etc. as well as expenses to operate, administer and manage the packing facilities.</td></tr><tr><td /><td /><td>Research costs, development costs not satisfying the criteria for capitalisaion and amortisation/depreciation of capitalised development costs are also recognised under production costs.</td></tr><tr><td /><td /><td>Furthermore, provisions for losses on construction contracts are recognised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial income and expenses</td></tr><tr><td /><td /><td>Financial income and expenses are recognised in the income statement at the amounts that relate to the reporting period. Net financials include interest income and expenses, realised and unrealised capital and exchange gains and losses on foreign currency transactions  and surcharges and allowances under the advance&#x1E;payment&#x1E;of&#x1E;tax scheme, etc.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income statement</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Intangible assets</td></tr><tr><td /><td /><td>Other intangible assets include software.</td></tr><tr><td /><td /><td>Other intangible assets are measured at cost less accumulated amortisation and impairment losses.</td></tr><tr><td /><td /><td>Gains or losses on the sale of intangible assets are recognised in the income statement under 'Other operating income' or âOther operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Other operating expenses</td></tr><tr><td /><td /><td>Other operating income and operating expenses comprise items of a secondary nature relative to the entity's core activities, including gains or losses on the sale of fixed assets.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Property, plant and equipment</td></tr><tr><td /><td /><td>Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr><tr><td /><td /><td>Gains or losses arising from the sale of items of property, plant and equipment are recognised in the income statement under 'Other operating income' or 'Other operating expenses', respectively. Gains and losses are calculated by reference to the difference between the selling price less selling expenses and the carrying amount at the time of sale.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Receivables</td></tr><tr><td /><td /><td>Receivables are measured at amortised cost, which usually corresponds to the nominal value. Provisions are made for bad debts on the basis of objective evidence that a receivable or a group of receivables are impaired. Provisions are made to the lower of the net realisable value and the carrying amount.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Revenue</td></tr><tr><td /><td /><td>Revenue include service fees for packing and labelling products to be distributed to group enterprises. Service fees are recognised exclusive of VAT.</td></tr><tr><td /><td /><td>Income from the supply of services is recognised as revenue with reference to the stage of completion.</td></tr><tr><td /><td /><td>Revenue is measured net of all types of discounts/rebates granted. Also, revenue is measured net of VAT and other indirect taxes charged on behalf of third parties.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Gross margin</td></tr><tr><td /><td /><td>Gross margin / Revenue * 100</td></tr><tr><td /><td /><td>EBIT margin</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Revenue * 100</td></tr><tr><td /><td /><td>Return on assets</td></tr><tr><td /><td /><td>Profit/loss from ordinary operating activites / Average assets * 100</td></tr><tr><td /><td /><td>Equity ratio</td></tr><tr><td /><td /><td>Closing equity / Equity &amp; liabilities at year-end * 100</td></tr><tr><td /><td /><td>Return on equity</td></tr><tr><td /><td /><td>Profit/loss for the year / Average  equity * 100</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Tax</td></tr><tr><td /><td /><td>Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td /><td /><td>The entity and its Danish group entities are taxed on a joint basis. The Danish income tax charge is allocated between profit&#x1E;making and loss&#x1E;making Danish entities in proportion to their taxable income (full allocation method).</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Income tax</td></tr><tr><td /><td /><td>Current tax payables and receivables are recognised in the balance sheet as the estimated tax charge in respect of the taxable income for the year, adjusted for tax on prior years' taxable income and tax paid on account.</td></tr><tr><td /><td /><td>Provisions for deferred tax are calculated, based on the liability method, of all temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, as well as temporary differences on non&#x1E;amortisable goodwill.</td></tr><tr><td /><td /><td>Deferred tax is measured according to the taxation rules and taxation rates in the respective countries applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the value at which they are expected to be utilised, either through elimination against tax on future earnings or through a set&#x1E;off against deferred tax liabilities within the same jurisdiction.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Financial ratios</td></tr><tr><td /><td /><td>Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios 'Recommendations and Financial Ratios 2010', cf. below</td></tr><tr><td /><td /><td>Definition of financial ratios</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Operating review</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>The company's business review</td></tr><tr><td /><td /><td>Biogen (Denmark) Manufacturing ApS main activities are production of biotechnological drug substance, packaging, labeling and quality control.</td></tr><tr><td /><td /><td>The company is part of US&#x1E;based Biogen Inc. working with development, manufacturing and marketing of innovative therapies within neurology and other therapeutic areas.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Post balance sheet events</td></tr><tr><td /><td /><td>Since the end of the financial year and until this date, there have been no events, which materially change the presentation of the annual report.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Special risks</td></tr><tr><td /><td /><td>For biotech companies the most significant risks relate to the generally large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry, including the market conditions for sale of pharmaceuticals.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td>Accounting policies</td></tr><tr><td /><td /><td>The annual report of Biogen (Denmark) Manufacturing ApS has been presented in accordance with the provisions of the Danish Financial Statements Act as regards large reporting class C enterprises.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Reporting currency</td></tr><tr><td /><td /><td>The financial statements are presented in Danish kroner.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Contingent liabilities and other financial obligations</td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >The company is jointly taxed with its parent, Biogen (Denmark) New Manufacturing ApS, which acts as management company, and is jointly and severally with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other financial obligations</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other rent and lease liabilities:</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Rent and lease liabilities</td><td width=""21%"" align=""right"" valign=""middle"" >13851</td><td width=""27%"" align=""right"" valign=""middle"" >6257</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Rent and lease liabilities concerning contracts which are interminable until 2014 with remaining contract terms of 1-5 years.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2014</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >31/12 2013</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""100%"" colspan=""6"" align=""left"" valign=""middle"" >Analysis of the company's share capital, DKK 390 thousand:</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >3,850 class Ashare(s) of DKK 100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >385</td><td width=""8%"" align=""right"" valign=""middle"" >385</td></tr><tr><td width=""73%"" colspan=""4"" align=""left"" valign=""middle"" >50 class Bshare(s) of DKK  100.00 each</td><td width=""19%"" align=""right"" valign=""middle"" >5</td><td width=""8%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""19%"" ></td><td width=""19%"" ></td><td width=""16%"" ></td><td width=""19%"" ></td><td width=""19%"" align=""right"" valign=""middle"" >390</td><td width=""8%"" align=""right"" valign=""middle"" >390</td></tr><tr><td colspan=""6""></td></tr><tr><td width=""19%"" ></td><td width=""81%"" colspan=""5"" align=""left"" valign=""middle"" >The company's share capital  has remained DKK 390 thousand over the past 5 years.</td></tr><tr><td colspan=""6""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Amortisation of intangible assets</td><td width=""21%"" align=""right"" valign=""middle"" >2692</td><td width=""27%"" align=""right"" valign=""middle"" >938</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Depreciation of property, plant and equpiment</td><td width=""21%"" align=""right"" valign=""middle"" >189760</td><td width=""27%"" align=""right"" valign=""middle"" >194162</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >192452</td><td width=""27%"" align=""right"" valign=""middle"" >195100</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""26%"" ></td><td width=""74%"" colspan=""3"" align=""left"" valign=""middle"" >Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with t.kr. 179,188 and Administrative expenses with t.kr. 13,264.</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Staff costs</td></tr><tr><td /><td colspan=""2"">Analysis of staff costs</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Staff costs are recognised in the income statement under the following items,</td></tr><tr><td /><td /><td colspan=""3"">Production costs at DKK 418,270 thousand,</td></tr><tr><td /><td /><td colspan=""3"">Administrative expenses at DKK 56,852 thousand</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">.Intangible assets</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial expenses</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Financial income</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >.Other operating expenses</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Other operating expenses include losses on the sale of property, plant and equipment, including other operating equipment.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Other payables</td></tr><tr><td width=""52%"" colspan=""2"" align=""left"" valign=""middle"" >Other accrued expenses</td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td width=""26%"" ></td><td width=""26%"" ></td><td width=""21%"" align=""right"" valign=""middle"" >113020</td><td width=""27%"" align=""right"" valign=""middle"" >123447</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about related parties with a controlling interest: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Related party</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Basis for control</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Arrowpark Interseas Limited</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Sovereign House 1416, Nelson Street Douglas, IM1 2AL, Isle of Man</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Luxembourg  Holding Sarl</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Luxembourg</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen (Denmark) New Manufacturing ApS</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen AllÃ© 1, 3400 HillerÃ¸d, Denmark</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Participating interest</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Information about consolidated financial statements: </td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Parent</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Domicile</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >Requisitioning of the parent's consolidated financial statements</td></tr><tr><td width=""26%"" colspan=""1"" align=""left"" valign=""middle"" >Biogen Inc.</td><td width=""47%"" colspan=""2"" align=""left"" valign=""middle"" >Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td><td width=""27%"" colspan=""1"" align=""left"" valign=""middle"" >The consolidated accounts of Biogen Inc. can be obtained by written application to Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Property, plant and equipment</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >.Provisions</td></tr><tr><td width=""50%"" ></td><td width=""50%"" colspan=""1"" align=""left"" valign=""middle"" >The provision for deferred tax primarily relates to timing differences in respect of intangible assets and property, plant and equipment.</td></tr><tr><td colspan=""2""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""20"">Alle belÃ¸b er angivet i 'x1000'</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >2014</td><td width=""28%"" align=""right"" valign=""middle"" >2013</td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td><td width=""28%"" colspan=""1"" align=""left"" valign=""middle"" >DKKt</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >.Revenue</td></tr><tr><td width=""4%"" ></td><td width=""96%"" colspan=""4"" align=""left"" valign=""middle"" >Geographical segmentation of revenue:</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >USA</td><td width=""20%"" align=""right"" valign=""middle"" >673559</td><td width=""28%"" align=""right"" valign=""middle"" >607772</td></tr><tr><td width=""4%"" ></td><td width=""48%"" colspan=""2"" align=""left"" valign=""middle"" >Europe</td><td width=""20%"" align=""right"" valign=""middle"" >480191</td><td width=""28%"" align=""right"" valign=""middle"" >446358</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""4%"" ></td><td width=""24%"" ></td><td width=""24%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >1153750</td><td width=""28%"" align=""right"" valign=""middle"" >1054130</td></tr><tr><td colspan=""5""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Tax for the year</td></tr></table><br><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Tax adjustments, prior years includes tax refunds received/paid between jointly taxed entities.</td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Omission to present a cash flow statement</td></tr><tr><td /><td /><td>With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity's cash flows are part of the consolidated cash flow statement for the parent company Biogen Inc.</td></tr></table>",4577416070.0,www.biogen.dk,26060702.0,30700228.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">The Board of Directors and the Executive Board have today discussed and approved the annual report of Biogen (Denmark) Manufacturing ApS for the financial year 1 January &#x1E; 31 December 2014.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">We have audited the financial statements of Biogen (Denmark) Manufacturing ApS  for the financial year 1 January &#x1E; 31 December 2014,  which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</td></tr></table>",8407000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""5"">Independent auditor's reports</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">Fee to the auditors appointed by the company in general meeting</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">5-year summary (in DKK thousands, except per share data)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""2"">By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to management is not disclosed.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Segment information</td></tr><tr><td /><td /><td>Segment information is given for revenue broken down by geographical segment. The segmentation is in accordance with the entity's internal financial management.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</td></tr></table>",Muna Yahaya,Marianne Leth,"PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab",Biogen (Denmark) Manufacturing ApS,Ernst og Young,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Opinion</td></tr><tr><td /><td /><td colspan=""4"">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January &#x1E; 31 December 2014 in accordance with the Danish Financial Statements Act.</td></tr></table>",Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""3"">We recommend the adoption of the annual report at the annual general meeting.</td></tr></table>",HillerÃ¸d,2014-12-31,2014-01-01,2015-05-13,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td colspan=""4"">Statement by management on the annual report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Auditor's responsibility</td></tr><tr><td /><td /><td colspan=""4"">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with international standards on auditing and additional requirements according to Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</td></tr><tr><td /><td /><td colspan=""4"">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view. The purpose is to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used, the reasonableness of accounting estimates made by management as well as the overall presentation of the financial statements.</td></tr><tr><td /><td /><td colspan=""4"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</td></tr><tr><td /><td /><td colspan=""4"">Our audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement of changes in equity</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td>Statutory CSR report</td></tr><tr><td /><td /><td>Corporate, Environmental, and Social Responsibility (Statutory report on CSR for the financial year 2014, cf. Section 99a of the Danish Financial Statements Act).  Biogen is an active participant in Pharmaceutical Supply Chain Initiatives (PSCI), and supports the Principles, which align with international frameworks and standards, including the United Nations Global Compact. PSCI is a group of 14 major pharmaceutical companies that share a vision of better social, economic and environmental outcomes as documented in the Pharmaceutical Industry Principles for Responsible Supply Chain Management.</td></tr><tr><td /><td /><td>Environmental Biogen (Denmark) Manufacturing ApS works to ensure more sustainable production. The Company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to discharge of waste water from production equipment and disposal of materials used in the production unit, labeling &amp; packaging or laboratory. At group level, the Company is taking additional initiatives aimed at more sustainable consumption of energy and water, reuse of materials and environmentally&#x1E;friendly disposal of waste.</td></tr><tr><td /><td /><td>Human rights In every country where we operate, Biogen follows all laws, regulations and international conventions related to human rights, including the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy and the Organization for Economic Co&#x1E;operation and Development Guidelines for Multinational Enterprises. The expectation to adhere to laws and regulations is outlined in our Code of Business Conduct.  Suppliers are also subject to our code. Additionally, we are working to improve the monitoring and enforcement of human rights in our supply chain through participation in the Pharmaceutical Supply Chain Initiative.</td></tr><tr><td /><td /><td>Society We have not identified any operations with significant potential or actual negative impacts on local communities. At our major locations, we have procedures in place to help ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. We also positively impact the communities where we live and work through our community programs.  The company strives to be a good corporate citizen. In January 2014 it was announced that Biogen is the second most sustainable company in the world according to the Global 100 rankings, an annual corporate sustainability assessment performed by the research firm Corporate Knights. Biogen has achieved listing on the Dow Jones Sustainability Index in the last three years in a row.   The information on global strategies, commitments and efforts regarding social responsibility and sustainability are published in the Biogen Annual report available at http://www.biogen.com/financial_reports .The Biogen Corporate Citizenship Report for 2014 is expected to be available at http://www.biogen.com /corporate citizenship from July 2015.</td></tr><tr><td /><td /><td>Account of the gender composition of management</td></tr><tr><td /><td /><td>The supervisory board consist of 2 female (67%) and 1 male (33%). Since the supervisory board consist of 3 persons it not possible to get a more equal composition between the genders and therefore we considered this to be equal represented. Going forward we expect an equal representation of genders to be continued.  The site leadership team currently consists of 42% female and 58% male and the gender composition is therefore considered to be equal represented. Going forward we expect an equal representation of genders to be continued.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Management's responsibility for the financial statements</td></tr><tr><td /><td /><td colspan=""4"">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act. Further, management is responsible for such internal control as it determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td /><td /><td colspan=""4"">Statement on the management's review</td></tr><tr><td /><td /><td colspan=""4"">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the management's review is consistent with the financial statements.</td></tr></table>",4577416000.0,chairman,RevisionspÃ¥tegning,urn:ofk:oid:5263684,indberetninger-20180424,2.5124266,26060702.0,,2018-03-30T13:15:57.975Z,2015-05-20T07:13:08.201Z,regnskab,0.0,,2014-12-31,2014-01-01,X15-AB-91-LQ,2015-05-20T07:13:08.423Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,380959000.0,,,,,,,,,,0.0,380959000.0,,,,,,,,,,,,,,,,,
